Prospective, Dose-Escalating, Investigator Initiated Trial to Evaluate the Safety and Efficacy of ZM-02 in Retinitis Pigmentosa
Latest Information Update: 17 Dec 2024
At a glance
- Drugs ZM 02 (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; Therapeutic Use
- Acronyms MOON
- Sponsors Zhongmou Therapeutics
Most Recent Events
- 15 Aug 2024 Status changed from not yet recruiting to recruiting.
- 08 Mar 2024 New trial record